| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $39.2M | -16.7% |
| Cost of Revenue | $39.2M | -16.7% |
| R&D Expense | $316.6M | +31.8% |
| SG&A Expense | $68.2M | +7.3% |
| Operating Income | -$349.4M | -33.5% |
| Pre-tax Income | -$311.4M | — |
| Income Tax | $0 | — |
| Net Income | -$311.4M | -39.1% |
| EPS (Basic) | -$3.69 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $357.0M | +196.9% |
| Current Assets | $871.2M | +70.7% |
| Total Assets | $1.74B | +78.2% |
| Current Liabilities | $83.2M | +22.8% |
| Total Liabilities | $163.1M | +14.6% |
| Stockholders' Equity | $1.58B | +89.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$232.9M | -19.7% |
| Capital Expenditures | $1.4M | -88.7% |
| Investing Cash Flow | -$521.1M | -29.0% |
| Financing Cash Flow | $990.7M | +62.7% |
| Free Cash Flow | -$234.3M | -13.0% |
| -23.8% |
| EPS (Diluted) | -$3.69 | -23.8% |